A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...
N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...